Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

595.64 +3.82 (+0.65%)
Streaming Delayed Price Updated: 3:36 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 258,772
Open 587.39
Bid (Size) 594.72 (8)
Ask (Size) 596.57 (8)
Prev. Close 591.82
Today's Range 582.07 - 600.54
52wk Range 327.73 - 611.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
From argenx SE
Via GlobeNewswire
(ARGX) - Analyzing argenx's Short Interest
Via Benzinga

Performance

YTD
+56.34%
+56.34%
1 Month
+6.28%
+6.28%
3 Month
+13.35%
+13.35%
6 Month
+63.76%
+63.76%
1 Year
+21.90%
+21.90%

More News

Read More
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Peering Into argenx's Recent Short Interest
Via Benzinga
The Latest Analyst Ratings For argenx
Via Benzinga
Peeling Back The Layers: Exploring argenx Through Analyst Insights
Via Benzinga
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
From argenx SE
Via GlobeNewswire
This eBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
argenx to Participate at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
Via Benzinga
This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
What 25 Analyst Ratings Have To Say About argenx
Via Benzinga
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
From argenx SE
Via GlobeNewswire
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
From argenx SE
Via GlobeNewswire
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
Via Talk Markets
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Via Benzinga
Exposures Product Safety
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.